ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Oct 16, 2020 13:44 JST
Source:
Eisai
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Pediatric Indication for Partial-Onset Seizures Accepted in China
TOKYO, Oct 16, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration.
The submission covering monotherapy for partial-onset seizures was based on subgroup analysis estimating monotherapy safety and efficacy within clinical studies of the combination therapy (Study 304, 305, 306, and 335) conducted globally including the United States, Europe and China on patients ages 12 years and older with partial-onset seizures (with or without secondarily generalized seizures). Additionally, results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea on untreated epilepsy patients ages 12 years to 74 years old with partial-onset seizures (with or without secondarily generalized seizures) were submitted as supplementary safety and efficacy data.
The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III clinical study (Study 311) of Fycompa as adjunctive therapy conducted globally on pediatric patients (ages 4 to less than 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures.
In China, it is estimated that there are approximately 9 million patients with epilepsy, and although onset occurs at any age, onset is most common in people aged 18 and younger and the elderly. As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs1, this is a disease with significant unmet medical needs.
Fycompa is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research
Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa has been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
Eisai considers neurology, including epilepsy, a therapeutic area of focus. With the acceptance of these additional applications regarding Fycompa in China, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.
For more information, visit
https://www.eisai.com/news/2020/pdf/enews202064pdf.pdf
.
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Toyota Gazoo Racing Hyped For Hypercar Debut
Apr 23, 2021 17:02 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
Apr 23, 2021 14:55 JST
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
Apr 23, 2021 13:02 JST
NEC, UN-Habitat and Peace Winds Japan provide thermography camera in Kenya to prevent the spread of COVID-19
Apr 23, 2021 10:16 JST
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
Apr 23, 2021 09:07 JST
MC and unerry Enter into Capital and Business Alliance
Apr 22, 2021 14:24 JST
Toyota Developing Hydrogen Engine Technologies Through Motorsports
Apr 22, 2021 14:06 JST
Honda e Triumphs at 2021 World Car Awards
Apr 22, 2021 08:07 JST
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
Apr 20, 2021 09:23 JST
Honda Exhibits the World Premiere of the "Honda SUV e:prototype" at Auto Shanghai 2021
Apr 20, 2021 00:01 JST
Mitsubishi Heavy Industries Engineering Launches "optimaX" Digital Service Platform
Apr 19, 2021 12:14 JST
Lexus Premieres New ES
Apr 19, 2021 10:56 JST
Toyota announces its new BEV series, Toyota bZ, in establishment of a full line-up of electrified vehicles
Apr 19, 2021 10:24 JST
New roads await the Toyota Yaris WRC in Croatia
Apr 16, 2021 18:09 JST
Showa Denko Announces Share Transfer with Change in Subsidiary
Apr 16, 2021 16:30 JST
Fujitsu Updates Group Environmental Plan to Achieve Validation of 1.5 degrees Celcius - Aligned Emissions Reduction Targets, Contribute to Sustainable Future
Apr 16, 2021 10:17 JST
Local Production of Hitachi Automatic Analyzer 3500 to Commence in China
Apr 15, 2021 16:42 JST
NextDecade and Mitsubishi Heavy Industries America Execute Engineering Services Agreement for Carbon Capture at Rio Grande LNG Project in Texas
Apr 15, 2021 13:56 JST
Fujitsu Fuels Big Data Innovation in Mobility Space with Launch of "Digital Twin Collector" Platform
Apr 15, 2021 10:44 JST
Mitsubishi Power Receives Order for Two Gas Turbines for 1,500MW Class GTCC Power Plant in Uzbekistan
Apr 14, 2021 15:36 JST
More Latest Release >>
Related Release
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
April 23 2021 13:55 JST
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
April 23 2021 12:02 JST
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
April 23 2021 08:07 JST
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
April 20 2021 08:23 JST
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
March 30 2021 11:42 JST
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
March 26 2021 08:16 JST
More Press release >>